FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362523809> ?p ?o ?g. }

• W4362523809 endingPage "175346662311645" @default.
• W4362523809 startingPage "175346662311645" @default.
• W4362523809 abstract "A twice-daily single inhaler triple therapy consisting of budesonide/glycopyrrolate/formoterol fumarate (BGF) was approved by the US Food and Drug Administration (FDA) in July 2020 as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The objective of this AURA study is to describe patient characteristics, exacerbation and treatment history, and healthcare resource utilization (HCRU) before BGF initiation to better inform treatment decisions for prescribers.This retrospective cohort study leveraged data of all payer types from IQVIA's Longitudinal Prescription Data (LRx) linked to Medical Data (Dx). Patients with COPD who had ⩾1 LRx claim for BGF between 1 October 2020 and 30 September 2021 were included. The date of first BGF claim was the index date. Patient demographic and clinical characteristics, history of COPD exacerbation or related event, treatment history, and HCRU were assessed during the 12 months before index (baseline).We identified 30,339 patients with COPD initiating BGF (mean age: 68.2 years; 57.1% female; 67.6% Medicare). Unspecified COPD (J44.9; 74.0%) was the most commonly coded COPD phenotype. The most prevalent respiratory conditions/symptoms were dyspnea (50.8%), lower respiratory tract infection (25.3%), and sleep apnea (19.0%). Uncomplicated hypertension (58.8%), dyslipidemia (43.9%), cardiovascular disease (41.4%), and heart failure (19.9%) were the most prevalent nonrespiratory conditions. During the 12-month baseline, 57.9% of patients had evidence of a COPD exacerbation or related event, and 14.9% had ⩾1 COPD-related emergency department (ED) visit; 21.0% of patients had evidence of prior triple therapy use, while 54.3% had ⩾1 oral corticosteroid (OCS) fill. Among OCS users, 29.9% had cumulative exposures >1000 mg [median [Q1-Q3] exposure: 520 (260-1183) mg].This real-world data analysis indicates that BGF is being initiated in patients with COPD experiencing symptoms and exacerbations despite current therapy, and among patients who have various chronic comorbidities, most often cardiopulmonary-related." @default.
• W4362523809 created "2023-04-06" @default.
• W4362523809 creator A5003697192 @default.
• W4362523809 creator A5012376116 @default.
• W4362523809 creator A5016898301 @default.
• W4362523809 creator A5032057767 @default.
• W4362523809 creator A5033974572 @default.
• W4362523809 creator A5037812787 @default.
• W4362523809 creator A5058911447 @default.
• W4362523809 creator A5065312871 @default.
• W4362523809 creator A5088768671 @default.
• W4362523809 date "2023-01-01" @default.
• W4362523809 modified "2023-10-16" @default.
• W4362523809 title "Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study" @default.
• W4362523809 cites W1971459182 @default.
• W4362523809 cites W1983772324 @default.
• W4362523809 cites W2018255767 @default.
• W4362523809 cites W2039206076 @default.
• W4362523809 cites W2045030413 @default.
• W4362523809 cites W2128750017 @default.
• W4362523809 cites W2136394058 @default.
• W4362523809 cites W2295597785 @default.
• W4362523809 cites W2520186351 @default.
• W4362523809 cites W2606085194 @default.
• W4362523809 cites W2624975405 @default.
• W4362523809 cites W2884384931 @default.
• W4362523809 cites W2914798425 @default.
• W4362523809 cites W2936962798 @default.
• W4362523809 cites W3007716362 @default.
• W4362523809 cites W3017018116 @default.
• W4362523809 cites W3082915598 @default.
• W4362523809 cites W3090626718 @default.
• W4362523809 cites W3144916199 @default.
• W4362523809 cites W3185698222 @default.
• W4362523809 cites W3215548254 @default.
• W4362523809 cites W4224435883 @default.
• W4362523809 cites W4239660703 @default.
• W4362523809 cites W4282970568 @default.
• W4362523809 cites W4289985772 @default.
• W4362523809 cites W2915502572 @default.
• W4362523809 doi "https://doi.org/10.1177/17534666231164534" @default.
• W4362523809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37013423" @default.
• W4362523809 hasPublicationYear "2023" @default.
• W4362523809 type Work @default.
• W4362523809 citedByCount "0" @default.
• W4362523809 crossrefType "journal-article" @default.
• W4362523809 hasAuthorship W4362523809A5003697192 @default.
• W4362523809 hasAuthorship W4362523809A5012376116 @default.
• W4362523809 hasAuthorship W4362523809A5016898301 @default.
• W4362523809 hasAuthorship W4362523809A5032057767 @default.
• W4362523809 hasAuthorship W4362523809A5033974572 @default.
• W4362523809 hasAuthorship W4362523809A5037812787 @default.
• W4362523809 hasAuthorship W4362523809A5058911447 @default.
• W4362523809 hasAuthorship W4362523809A5065312871 @default.
• W4362523809 hasAuthorship W4362523809A5088768671 @default.
• W4362523809 hasBestOaLocation W43625238091 @default.
• W4362523809 hasConcept C118552586 @default.
• W4362523809 hasConcept C126322002 @default.
• W4362523809 hasConcept C177713679 @default.
• W4362523809 hasConcept C1862650 @default.
• W4362523809 hasConcept C2776042228 @default.
• W4362523809 hasConcept C2776136866 @default.
• W4362523809 hasConcept C2776780178 @default.
• W4362523809 hasConcept C2777014857 @default.
• W4362523809 hasConcept C2777450039 @default.
• W4362523809 hasConcept C2779871671 @default.
• W4362523809 hasConcept C2780261241 @default.
• W4362523809 hasConcept C2780667556 @default.
• W4362523809 hasConcept C2780724011 @default.
• W4362523809 hasConcept C71924100 @default.
• W4362523809 hasConceptScore W4362523809C118552586 @default.
• W4362523809 hasConceptScore W4362523809C126322002 @default.
• W4362523809 hasConceptScore W4362523809C177713679 @default.
• W4362523809 hasConceptScore W4362523809C1862650 @default.
• W4362523809 hasConceptScore W4362523809C2776042228 @default.
• W4362523809 hasConceptScore W4362523809C2776136866 @default.
• W4362523809 hasConceptScore W4362523809C2776780178 @default.
• W4362523809 hasConceptScore W4362523809C2777014857 @default.
• W4362523809 hasConceptScore W4362523809C2777450039 @default.
• W4362523809 hasConceptScore W4362523809C2779871671 @default.
• W4362523809 hasConceptScore W4362523809C2780261241 @default.
• W4362523809 hasConceptScore W4362523809C2780667556 @default.
• W4362523809 hasConceptScore W4362523809C2780724011 @default.
• W4362523809 hasConceptScore W4362523809C71924100 @default.
• W4362523809 hasFunder F4320307770 @default.
• W4362523809 hasLocation W43625238091 @default.
• W4362523809 hasLocation W43625238092 @default.
• W4362523809 hasOpenAccess W4362523809 @default.
• W4362523809 hasPrimaryLocation W43625238091 @default.
• W4362523809 hasRelatedWork W1544063073 @default.
• W4362523809 hasRelatedWork W1991813083 @default.
• W4362523809 hasRelatedWork W2080041490 @default.
• W4362523809 hasRelatedWork W2082550557 @default.
• W4362523809 hasRelatedWork W2099652899 @default.
• W4362523809 hasRelatedWork W2130094601 @default.
• W4362523809 hasRelatedWork W2314044715 @default.
• W4362523809 hasRelatedWork W2316642373 @default.
• W4362523809 hasRelatedWork W3094817130 @default.

• next